European equities traded in the US as American depositary receipts were moving higher late Friday morning, rising 0.55% to 1,424.23 on the S&P Europe Select ADR Index, which is poised to end the week about 0.31% higher.
From continental Europe, the gainers were led by biopharmaceutical company Genfit (GNFT) and semiconductor company Sequans Communications (SQNS), which advanced 10% and 2.5% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and pharmaceutical company Novo Nordisk (NVO), which increased 2% and 1.8% respectively.
The decliners from continental Europe were led by medical device maker EDAP TMS (EDAP) and biopharmaceutical company Grifols (GRFS), which fell 2.5% and 1.6% respectively. They were followed by biotech firm Evaxion Biotech (EVAX) and telecommunications company Nokia (NOK), which were down 1.1% and 0.6% respectively.
From the UK and Ireland, the gainers were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Bicycle Therapeutics (BCYC), which climbed 9.9% and 3.5% respectively. They were followed by software firm Endava (DAVA) and biotech firm Autolus Therapeutics (AUTL), which rose 2.8% and 1.6% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Akari Therapeutics (AKTX) and insurance company Prudential (PUK), which lost 8.4% and 1.3% respectively. They were followed by telecommunications operator Vodafone Group (VOD) and pharmaceutical company GSK (GSK), which were off 0.9% each.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。